Stocks and Investing
Stocks and Investing
Fri, August 4, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Andrew Fein Reiterated (BCRX) at Strong Buy and Held Target at $30 on, Aug 4th, 2023
Andrew Fein of HC Wainwright & Co., Reiterated "BioCryst Pharmaceuticals, Inc." (BCRX) at Strong Buy and Held Target at $30 on, Aug 4th, 2023.
Andrew has made no other calls on BCRX in the last 4 months.
There are 3 other peers that have a rating on BCRX. Out of the 3 peers that are also analyzing BCRX, 0 agree with Andrew's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Andrew
- Serge Belanger of "Needham" Reiterated at Strong Buy with Decreased Target to $12 on, Thursday, August 3rd, 2023
- Tazeen Ahmad of "B of A Securities" Upgraded from Hold to Strong Buy and Held Target at $10 on, Thursday, July 13th, 2023
- Liisa Bayko of "Evercore ISI Group" Maintained at Buy with Decreased Target to $10 on, Thursday, April 20th, 2023
Contributing Sources